CRISPR Therapeutics AG (CRSP) Other Non-Current Assets (2015 - 2026)

CRISPR Therapeutics AG has disclosed Other Non-Current Assets across 12 years of filings, most recently posting $29.0 million for Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $29.0 million, up 262.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.0 million (up 262.02% YoY), and the FY2025 annual result was $7.6 million, down 51.99% from the prior year.
• Other Non-Current Assets came in at $29.0 million for Q1 2026 at CRISPR Therapeutics AG, up from $7.6 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $29.0 million in Q1 2026 to a low of $7.6 million in Q4 2025.
• The 5-year median for Other Non-Current Assets is $11.7 million (2023), against an average of $13.1 million.
• Across the five-year window, Other Non-Current Assets tumbled 51.99% in 2025 and soared 262.02% in 2026, its largest moves.
• CRISPR Therapeutics AG's Other Non-Current Assets stood at $11.6 million in 2022, then retreated by 0.38% to $11.6 million in 2023, then jumped by 36.56% to $15.8 million in 2024, then sank by 51.99% to $7.6 million in 2025, then soared by 281.36% to $29.0 million in 2026.
• The last three Other Non-Current Assets figures came in at $29.0 million (Q1 2026), $7.6 million (Q4 2025), and $24.3 million (Q3 2025), per Business Quant data.